# Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

> **NCT00454168** · PHASE3 · UNKNOWN · sponsor: **The Vaccine Company** · enrollment: 244 (estimated)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** PR1 leukemia peptide vaccine
- **BIOLOGICAL:** sargramostim
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00454168
- **Lead sponsor:** The Vaccine Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-05
- **Primary completion:** 2009-04
- **Final completion:** —
- **Target enrollment:** 244 (ESTIMATED)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454168, "Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00454168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*